key: cord-0732820-g0fam0fm
authors: Miller, T. E.; Garcia Beltran, W. F.; Bard, A. Z.; Gogakos, T.; Anahtar, M. N.; Astudillo, M. G.; Yang, D.; Thierauf, J.; Fisch, A. S.; Mahowald, G. K.; Fitzpatrick, M. J.; Nardi, V.; Feldman, J.; Hauser, B. M.; Caradonna, T. M.; Marble, H. D.; Ritterhouse, L. L.; Turbett, S. E.; Batten, J.; Georgantas, N. Z.; Alter, G.; Schmidt, A. G.; Harris, J. B.; Gelfand, J. A.; Poznansky, M. C.; Bernstein, B. E.; Louis, D. N.; Dighe, A.; Charles, R. C.; Ryan, E. T.; Branda, J. A.; Pierce, V. M.; Murali, M. R.; Iafrate, A. J.; Rosenberg, E. S.; Lennerz, J.
title: Clinical Sensitivity and Interpretation of PCR and Serological COVID-19 Diagnostics for Patients Presenting to the Hospital
date: 2020-06-20
journal: nan
DOI: 10.1101/2020.06.19.20135723
sha: 3f8b5565e562d016705fd11caed73b1db08556c7
doc_id: 732820
cord_uid: g0fam0fm

Introduction: The diagnosis of COVID-19 requires integration of clinical and laboratory data. SARS-CoV-2 diagnostic assays play a central role in diagnosis and have fixed technical performance metrics. Interpretation becomes challenging because the clinical sensitivity changes as the virus clears and the immune response emerges. Our goal was to examine the clinical sensitivity of two most common SARS-CoV-2 diagnostic test modalities, polymerase chain reaction (PCR) and serology, over the disease course to provide insight into their clinical interpretation in patients presenting to the hospital. Methods: A single-center, retrospective study. To derive clinical sensitivity of PCR, we identified 209 PCR-positive SARS-CoV-2 patients with multiple PCR test results (624 total PCR tests) and calculated daily sensitivity from date of symptom onset or first positive test. To calculate daily clinical sensitivity by serology, we utilized 157 PCR-positive patients with a total of 197 specimens tested by enzyme-linked immunosorbent assay for IgM, IgG, and IgA anti-SARS-CoV-2 antibodies. Results: Clinical sensitivity of PCR decreased with days post symptom onset with >90% clinical sensitivity during the first 5 days after symptom onset, 70-71% from days 9-11, and 30% at day 21. In contrast, serological sensitivity increased with days post symptom onset with >50% of patients seropositive by at least one antibody isotype after day 7, >80% after day 12, and 100% by day 21. Conclusion: PCR and serology are complimentary modalities that require time-dependent interpretation. Superimposition of sensitivities over time indicate that serology can function as a reliable diagnostic aid indicating recent or prior infection.

CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 20, 2020. Here, we share our experience of SARS-CoV-2 PCR sensitivity and separately obtained 83 IgM, IgA, and IgG sensitivity of an in-house enzyme-linked immunosorbent assay 84 (ELISA) during the natural course of disease in a cohort of patients presenting to the 85 hospital. 86 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 20, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 20, 2020. . https://doi.org/10.1101/2020.06.19.20135723 doi: medRxiv preprint CoV-2 PCR-positive patients and for each sample, we determined the days post symptom 119 onset at the collection date and calculated daily sensitivity for each antibody isotype as 120 well as sensitivity of any isotype. We plotted the sensitivity for both test modalities as 121 percentages per overlapping 5-day leading intervals against the days since symptom onset 122 (see supplement). 123 Table 1 ). We compared this 133 subset to all tested patients (Supplemental Figure 1 , Supplemental Table 1 ) and 134 contingency analysis of the multi-PCR vs. all single PCR-positive patient subset showed 135 no significant differences in age, gender, and test type (Supplemental Table 1 , 136

Supplemental Figure 2 ). Thus, we consider the multi-PCR subset is demographically 137 representative of our tested patient population. 138

To derive clinical sensitivity over disease course, we needed to define an anchor point. 139

We chose two different anchor points: symptom onset (subjective) and first positive test 140 (objective). First, we examined the time-course by anchoring test results to the day of 141 symptom onset (Figure 1, Supplemental Figure 3 ). Clinical sensitivity remains above 142 90% for the first 5 days after symptom onset. In our cohort of patients presenting to the 143 hospital, patients were admitted to the hospital a median of 8 days after symptom onset 144 (interquartile range: 4-16 days; mean: 10 days), and between days 6-8, the clinical 145 sensitivity of PCR ranged from 84-76%. On subsequent days the sensitivity decreases, 146 and at day 18 the sensitivity decreases below 50%. We also compared sensitivity data 147 from an earlier study of mildly symptomatic patients(4) and noted a steeper PCR 148 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 20, 2020. . https://doi.org/10.1101/2020.06.19.20135723 doi: medRxiv preprint sensitivity decline, consistent with viral levels dropping more quickly in this population 149 (Supplemental Figure 4) . This data provides sensitivity estimates at the time of 150 presentation (e.g., a patient presents at day 10 after symptom onset). Second, we also 151 modeled how PCR sensitivity decreases over time after the first positive PCR-test 152 (Table 1) . 162

For some patients, we were able to assess serology at multiple time points (n=591 total 163 isotype tests on 197 total specimens). Anchoring our serologic results to days after 164 symptom onset shows that seroconversion starts as early as symptom onset, is detectable 165 in 50% of subjects after day 7, and continues to increase with >80% of patients showing 166 seropositivity after day 12 (Table 2, Table 2 ). In the subset of patients with multiple serological tests we saw isotype 168 switching occur as short as 1-4 days, consistent with recent reports(5). Of note, we 169 detected IgA prior to IgM or IgG in a number of individuals, with 2 subjects having only 170 detectable IgA within 3 days of symptom onset. We also documented cases of IgG 171 positivity prior to IgM or IgA, highlighting the utility of measuring seroconversion using 172 all 3 isotypes (Supplemental Table 3 , Supplemental Figure 6 ). The superimposition of 173 serologic sensitivities with PCR sensitivities shows that, after day 7, seroconversion is a 174 reliable diagnostic aid indicating recent or prior infection (Figure 1) . 175 176 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 20, 2020. We present the dynamic clinical sensitivity of SARS-CoV-2 PCR and our serology 178 platform in patients presenting to the hospital. We performed this single-center, 179 retrospective analysis to share early real-world evidence that can inform interpretation of 180 PCR and serologic testing. We focused on assessing the clinical utility of both modalities 181 in conjunction by direct superimposition of both sensitivity time courses. The direct 182 superimposition shows that serology can function as a reliable diagnostic aid indicating 183 recent or prior infection -in particular at times when PCR sensitivity is lower than 70%. (2) PCR is the diagnostic gold standard during acute infection. PCR-testing using 205 consensus primers has an estimated specificity of >99% (15). Based on early reports 206 from Wuhan(16) the overall clinical sensitivity is reported around 70%. We found a 207 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 20, 2020. However, our data clearly shows that there is a window period (day 6-12 from symptom 235 onset) when clinical sensitivity of PCR and serological assays are below 90%. In a 236 symptomatic patient, if multiple PCR tests are negative and serological results after 8-12 237 days are also negative, we believe the likelihood of active SARS-CoV-2 infection to be 238 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 20, 2020. Notably, the eclipse period ranges from 2-14 days (18-21) and some patients already 250 mounted a serologic response at the time of presentation, which can be taken as an 251 argument for the early y-axis deviation from zero in the serology curve and a 252 confirmation of date of symptom onset as an imperfect marker. We caution that the 253 presented serology data are specific to our ELISA, and we cannot extrapolate to anti- unlikely to provide protective immunity as nucleocapsid protein is inaccessible to 265 antibodies in an intact virus. Therefore, serology results also likely depend on the 266 specific antigen being employed in testing. Finally, our multi-PCR cohort and serologic 267 patient cohort are largely non-overlapping (n=20/209) PCR-positive patient. To enable 268 additive sensitivity calculations from combined PCR and serology assays, prospective 269 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 20, 2020. . https://doi.org/10.1101/2020.06.19.20135723 doi: medRxiv preprint and systematically obtained repeated parallel PCR and quantitative serologic data will be 270 necessary. 271

Determining the clinical sensitivity of SARS-CoV-2 diagnostic tests is an area that does 273 not have time to wait for full, exact analysis during an ongoing pandemic. Our real-274 world data outline the strengths and weaknesses of two SARS-CoV-2 test modalities over 275 the natural course of infection. We hope these data, in conjunction with the 5 diagnostic 276 principles for consideration, can contribute to effective utilization and interpretation of 277 COVID-19 related laboratory data for patient care. 278 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 20, 2020. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 20, 2020. . https://doi.org/10.1101/2020.06.19.20135723 doi: medRxiv preprint

Diagnostic 294 Testing for Severe Acute Respiratory Syndrome-Related Coronavirus 2: A Narrative 295

Profiling Early Humoral Response 297 to Diagnose Novel Coronavirus Disease (COVID-19)

Interpreting Diagnostic Tests for SARS-CoV-2

Virological assessment of hospitalized patients with COVID-2019

Temporal dynamics in viral 303 shedding and transmissibility of COVID-19

Evidence based 305 management guideline for the COVID-19 pandemic -Review article

COVID-19 308 diagnosis and management: a comprehensive review

Laboratory Diagnosis of COVID-19: 310 Current Issues and Challenges

COVID-19 diagnostics in context

SARS-CoV-2 serology: Test, test, 314 test, but interpret with caution

COVID-19 pandemic-a focused review for clinicians

Multi-tiered screening and 318 diagnosis strategy for COVID-19: a model for sustainable testing capacity in response to 319 pandemic

Waiting for Certainty on Covid-19

Antibody Tests -At What Cost?

Antibody responses to 16

Detection of SARS-CoV-2 in

Different Types of Clinical Specimens

Profile of IgG and IgM antibodies 328 against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Incubation period of 2019 novel coronavirus 331 (2019-nCoV) infections among travellers from Wuhan, China

The Incubation 334 Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed 335 Cases: Estimation and Application

of Novel Coronavirus-Infected Pneumonia

Incubation Period and Other Epidemiological Characteristics of

Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data

CoV-2 in patients of novel coronavirus disease 2019

Potent neutralizing antibodies from COVID-19 patients define multiple targets of 347 vulnerability

Identification of a critical neutralization 349 determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: 350 importance for designing SARS vaccines

SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal 353 model

SARS-CoV-2 by human antibody heavy-chain variable domains isolated from a large 356 library with a new stable scaffold

Potent human neutralizing antibodies elicited by SARS-CoV-2 infection

The authors thank all patients and laboratory staff for making this study possible. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted June 20, 2020. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 20, 2020. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 20, 2020. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted June 20, 2020. . https://doi.org/10.1101/2020.06.19.20135723 doi: medRxiv preprint